Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2025)

Monopar Therapeutics has reported Change in Accured Expenses for 9 years, with the latest figure at $738682.0 in Q4 2025.

• Quarterly Change in Accured Expenses fell 34.92% year-over-year to $738682.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $388218.0 (down 23.4% YoY) and the FY2025 annual result came in at $388218.0, down 23.4% from the prior year.
• Change in Accured Expenses grew to $738682.0 in Q4 2025 per MNPR's latest filing, from $355101.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.2 million in Q4 2022 and troughed at -$770968.0 in Q1 2025.
• A 5-year average of $75986.3 and a median of -$2379.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses slumped 10489.49% in 2023, then soared 1137.63% in 2025.
• Over 5 years, Change in Accured Expenses stood at $403967.0 in 2021, then soared by 196.03% to $1.2 million in 2022, then tumbled by 117.81% to -$212999.0 in 2023, then jumped by 632.91% to $1.1 million in 2024, then sank by 34.92% to $738682.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $738682.0, $355101.0, and $65403.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.